These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 30273261)

  • 21. Cardiovascular Disease, Mortality Risk, and Healthcare Costs by Lipoprotein(a) Levels According to Low-density Lipoprotein Cholesterol Levels in Older High-risk Adults.
    Zhao Y; Delaney JA; Quek RG; Gardin JM; Hirsch CH; Gandra SR; Wong ND
    Clin Cardiol; 2016 Jul; 39(7):413-20. PubMed ID: 27177347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients With Manifest Arterial Disease.
    van den Berg MJ; van der Graaf Y; de Borst GJ; Kappelle LJ; Nathoe HM; Visseren FLJ;
    Am J Cardiol; 2016 Sep; 118(6):804-810. PubMed ID: 27471056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of cardiovascular events in patients at optimal values for combined lipid parameters.
    Stanek EJ; Sarawate C; Willey VJ; Charland SL; Cziraky MJ
    Curr Med Res Opin; 2007 Mar; 23(3):553-63. PubMed ID: 17357251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
    J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of cardiovascular disease risk associated with 3 lipid measures in Japanese adults.
    Takeuchi T; Nemoto K; Takahashi O; Urayama KY; Deshpande GA; Izumo H
    J Clin Lipidol; 2014; 8(5):501-9. PubMed ID: 25234563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cholesterol goal attainment in hypertensive patients: the impact of metabolic syndrome components.
    Rodrigues CJ; Ribeiro HF; Ribeiro AB; Zanella MT; Batista MC
    Metab Syndr Relat Disord; 2012 Jun; 10(3):195-201. PubMed ID: 22313142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease.
    Nishizawa Y; Shoji T; Kakiya R; Tsujimoto Y; Tabata T; Ishimura E; Nakatani T; Miki T; Inaba M
    Kidney Int Suppl; 2003 May; (84):S117-20. PubMed ID: 12694324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of non-HDL cholesterol as a predictor of non-fatal cardiovascular events in a prospective population cohort.
    Carbayo Herencia JA; Simarro Rueda M; Palazón Bru A; Molina Escribano F; Ponce García I; Artigao Ródenas LM; Caldevilla Bernardo D; Divisón Garrote JA; Gil Guillén VF;
    Clin Investig Arterioscler; 2018; 30(2):64-71. PubMed ID: 29395492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study.
    Howard BV; Robbins DC; Sievers ML; Lee ET; Rhoades D; Devereux RB; Cowan LD; Gray RS; Welty TK; Go OT; Howard WJ
    Arterioscler Thromb Vasc Biol; 2000 Mar; 20(3):830-5. PubMed ID: 10712410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm.
    Sever PS; Poulter NR; Chang CL; Thom SA; Hughes AD; Welsh P; Sattar N;
    J Am Coll Cardiol; 2013 Aug; 62(8):717-29. PubMed ID: 23948514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study.
    Koopal C; Retterstøl K; Sjouke B; Hovingh GK; Ros E; de Graaf J; Dullaart RP; Bertolini S; Visseren FL
    Atherosclerosis; 2015 May; 240(1):90-7. PubMed ID: 25768710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Global cardiovascular mortality risk in the adult Polish population: prospective assessment of the cohorts studied in multicentre national WOBASZ and WOBASZ Senior studies.
    Piotrowski W; Waśkiewicz A; Cicha-Mikołajczyk A
    Kardiol Pol; 2016; 74(3):262-73. PubMed ID: 26365939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
    Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
    Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive value of traditional risk factors for cardiovascular disease in older people: A systematic review.
    van Bussel EF; Hoevenaar-Blom MP; Poortvliet RKE; Gussekloo J; van Dalen JW; van Gool WA; Richard E; Moll van Charante EP
    Prev Med; 2020 Mar; 132():105986. PubMed ID: 31958478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
    Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
    Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Obesity, ultrasound indexes of fat depots and lipid goal attainment in patients with high and very high cardiovascular risk: A novel approach towards better risk reduction.
    Haberka M; Okopień B; Gąsior Z
    Nutr Metab Cardiovasc Dis; 2016 Feb; 26(2):123-33. PubMed ID: 26830392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004.
    Ghandehari H; Kamal-Bahl S; Wong ND
    Am Heart J; 2008 Jul; 156(1):112-9. PubMed ID: 18585505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL.
    Averna M; Stroes E;
    Atheroscler Suppl; 2017 Apr; 26():16-24. PubMed ID: 28434480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of lipid variables as predictors of cardiovascular disease in the Asia Pacific region.
    Barzi F; Patel A; Woodward M; Lawes CM; Ohkubo T; Gu D; Lam TH; Ueshima H;
    Ann Epidemiol; 2005 May; 15(5):405-13. PubMed ID: 15840555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.